- Home
- EWTX vs GAM Comparison
EWTX vs GAM Comparison
Compare EWTX & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- GAM
- Stock Information
- Founded
- EWTX 2017
- GAM 1927
- Country
- EWTX United States
- GAM United States
- Employees
- EWTX N/A
- GAM N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- GAM Investment Managers
- Sector
- EWTX Health Care
- GAM Finance
- Exchange
- EWTX Nasdaq
- GAM Nasdaq
- Market Cap
- EWTX 1.2B
- GAM 1.2B
- IPO Year
- EWTX 2021
- GAM N/A
- Fundamental
- Price
- EWTX $14.58
- GAM $51.74
- Analyst Decision
- EWTX Buy
- GAM
- Analyst Count
- EWTX 8
- GAM 0
- Target Price
- EWTX $40.13
- GAM N/A
- AVG Volume (30 Days)
- EWTX 1.2M
- GAM 20.1K
- Earning Date
- EWTX 05-08-2025
- GAM 01-01-0001
- Dividend Yield
- EWTX N/A
- GAM 5.74%
- EPS Growth
- EWTX N/A
- GAM N/A
- EPS
- EWTX N/A
- GAM 11.67
- Revenue
- EWTX N/A
- GAM N/A
- Revenue This Year
- EWTX N/A
- GAM N/A
- Revenue Next Year
- EWTX N/A
- GAM N/A
- P/E Ratio
- EWTX N/A
- GAM $3.95
- Revenue Growth
- EWTX N/A
- GAM N/A
- 52 Week Low
- EWTX $10.60
- GAM $37.32
- 52 Week High
- EWTX $38.12
- GAM $46.48
- Technical
- Relative Strength Index (RSI)
- EWTX 41.67
- GAM 60.94
- Support Level
- EWTX $13.82
- GAM $51.08
- Resistance Level
- EWTX $17.30
- GAM $52.19
- Average True Range (ATR)
- EWTX 1.02
- GAM 0.76
- MACD
- EWTX 0.32
- GAM 0.24
- Stochastic Oscillator
- EWTX 30.43
- GAM 89.91
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.